GlassScriptPhysician profile
Christopher Frick
NPI 1700010014
$46,332.01
in general payments reported to CMS, 2019-2025
23 companies · $819 in 2025
The $819 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,157 · 2022: $11K · 2023: $21K · 2024: $7,230 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $3,367 · Food and Beverage: $2,936 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,667.68 |
| Travel and Lodging | $3,366.79 |
| Food and Beverage | $2,935.71 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43,597.03 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $998.47 | 2021-2025 | Wainua, Farxiga, Brilinta |
| Abiomed | $239.58 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $218.08 | 2022-2025 | |
| Amgen INC. | $215.15 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $158.14 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System, Avvigo Guidance System |
| Actelion Pharmaceuticals US, INC. | $116.74 | 2023-2024 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $116.70 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $95.38 | 2024-2025 | Verquvo, Winrevair |
| E.R. Squibb & Sons, L.L.C. | $80.39 | 2024-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.81 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $67.37 | 2024 | Xarelto |
| Chiesi USA, INC. | $58.13 | 2022-2025 | Kengreal, Cleviprex |
| Terumo Medical Corporation | $55.18 | 2023-2024 | Angio-Seal, Metacross Otw, Glidesheath Slender |
| Pfizer INC. | $39.80 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $39.76 | 2024 | Arcalyst |
| Phathom Pharmaceuticals, INC. | $33.43 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $29.51 | 2024-2025 | Nexletol |
| Heartflow, INC. | $28.99 | 2025 | |
| Novo Nordisk INC | $22.84 | 2025 | Wegovy |
| Lilly USA, LLC | $20.51 | 2025 | Zepbound |
| Daiichi Sankyo INC. | $17.18 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.84 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Frick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.